WHAT IS CLAIMED IS:

1. Use of an anti-sclerostin antibody in the manufacture of a medicament for increasing alveolar bone height in a subject suffering from alveolar bone loss, wherein the anti-sclerostin antibody comprises CDR-H1 of SEQ ID NO:245, CDR-H2 of SEQ ID NO:246, CDR-H3 of SEQ ID NO:247, CDR-L1 of SEQ ID NO:78, CDR-L2 of SEQ ID NO:79, and CDR-L3 of SEQ ID NO:80.

~~binds to SEQ ID NO: 1) and wherein the anti-sclerostin antibody cross-blocks or is cross-blocked by an antibody that comprises~~

~~a) CDR sequences of SEQ ID NOs:48, 49, and 50 and CDR sequences of SEQ ID NOs:45, 46, and 47;~~

~~b) CDR sequences of SEQ ID NOs:42, 43, and 44 and CDR sequences of SEQ ID NOs:39, 40, and 41;~~

~~c) CDR sequences of SEQ ID NOs:275, 276, and 277 and CDR sequences of SEQ ID NOs:287, 288, and 289;~~

~~d) CDR sequences of SEQ ID NOs:278, 279, and 280 and CDR sequences of SEQ ID NOs:290, 291, and 292;~~

~~e) CDR sequences of SEQ ID NOs:281, 282, and 283 and CDR sequences of SEQ ID NOs:293, 294, and 295;~~

~~f) CDR sequences of SEQ ID NOs:284, 285, and 286 and CDR sequences of SEQ ID NOs:296, 297, and 298;~~

~~g) CDR sequences of SEQ ID NOs:116, 237, and 238 and CDR sequences of SEQ ID NOs:266, 267, and 268; or~~

~~h) CDR sequences of SEQ ID NOs:242, 243, and 244 and CDR sequences of SEQ ID NOs:272, 273, and 274.~~

2. The use of claim 1, wherein the anti-sclerostin antibody is to be administered in an amount from about 120-270 mg.

3. The use of claim 1, wherein the anti-sclerostin antibody is to be administered twice a week.

4. The use of claim 1, wherein the anti-sclerostin antibody is to be administered locally to diseased gingival area or diseased periodontal pocket of the subject.

5. The use of any one of claims 1-4, wherein the use for increasing of alveolar bone height in a subject suffering from alveolar bone loss~~treating~~ further comprises that a standard of care therapeutic selected from the group consisting of doxycycline or chemically modified tetracycline-3 (CMT-3) is to be administered prior to administration the anti-sclerostin antibody.

6. The use of any one of claims 1-5, wherein the use for increasing alveolar bone height in a subject suffering from alveolar bone loss~~treatment~~ further comprises that a second bone-enhancing therapeutic is to be administered, selected from the group consisting of parathyroid hormone, teriparatide, a bisphosphonate, a Receptor Activator of Nuclear Kappa B Ligand (RANKL) antibody and a dickkopf (DKK-1) antibody.

7. The use of claim 7, wherein the second bone-enhancing therapeutic is to be administered after the treatment period with the anti-sclerostin antibody has ended.

8. The use of claim 1, wherein the anti-sclerostin antibody is to be administered for a second period of time in an amount sufficient to maintain alveolar bone.

9. The use of any one of claims 1-8, wherein the anti-sclerostin antibody is an immunoglobulin comprising a heavy chain and a light chain.

10. The use of any one of claims 1-9, wherein the anti-sclerostin antibody demonstrates a binding affinity for sclerostin of SEQ ID NO:1 of less than or equal to 1×10^{-9} M.

11. The use of any one of claims 1-10, wherein anti-sclerostin antibody comprises heavy chains comprising SEQ ID NO: 378 and light chains comprising SEQ ID NO 376.